ArticleJACS Au2026
Ultrasound-Responsive Nanoparticles Enable Hydrophobic Antibiotic Release and Deep Penetration for Biofilm Treatment.
Article in JACS Au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Localized delivery of antibiotics is a promising strategy that leads to transformative treatment pathways of bacterial biofilms and increases the effectiveness of their administration in contrast to traditional delivery methods requiring high antibiotic doses. Hydrophobic antibiotics have poor activity against bacterial biofilms due to their limited penetration and are particularly challenging to deliver. Nanoparticles are ideal drug delivery agents to achieve spatially controlled delivery, but commonly their designs are either soft or porous, which limits temporally triggered release, with the result that most of the antibiotic does not reach deeply into the biofilm. In this study, we present designs of nonporous silica nanoparticles that encapsulate a lipophilic antibiotic, rifampicin, with noncovalent interactions and enable controlled release triggered by Low-Frequency Ultrasound (LFUS).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.